Supporting Information for

A Push–Pull Macrocycle With Both Linearly Conjugated and Cross-Conjugated Bridges

Wade C. W. Leu and C. Scott Hartley

Department of Chemistry & Biochemistry, Miami University, Oxford, OH 45056, USA

Supplemental Figures
Figure S1. UV–vis and fluorescence spectra of H(mP/Th)H, D(mP/Th)D, and A(mP/Th)A in cyclohexane (black) and CH ₂ Cl ₂ (blue)
Figure S2. UV-vis and fluorescence spectra of D(mP/Th)A in in cyclohexane (black), toluene (blue), 1,4-dioxane (red), CHCl ₃ (green) and CH ₂ Cl ₂ (purple)4
Figure S3. Optimized geometries and frontier molecular orbitals of A(mP/Th)A' and D(mP/Th)D'4
Figure S4. TD-DFT-calculated UV-vis transitions for H(mP/Th)H' , D(mP/Th)D' , A(mP/Th)A' , and D(mP/Th)A' at the TD/PCM(Cyclohexane)/CAM-B3LYP/6-311+G(2d,2p)//PCM/B3LYP/6-31+G(d,p) level. The solid lines are the simulated spectra based on the transitions with a 0.333 eV half-width at half-height. The dotted lines are the experimental spectra in cyclohexane (a.u.)
Figure S5. Lowest energy UV-vis transition (cyclohexane) vs PCM(cyclohexane)/CAM-B3LYP/6- 311+G(2d,2p)//B3LYP/6-31+G(d) HOMO-LUMO gap for macrocycles H(mP/Th)H, D(mP/Th)D, and A(mP/Th)A
Figure S6. Comparison of the UV-vis (left) and fluorescence (right) spectra of D(mP/Th)A, D(Th)A, and D(Th) ₂ A. The spectra of the latter two compounds were previously reported. ¹
Lippert-Mataga Analysis6
Figure S7. Lippert–Mataga plots of D(mP/Th)A fluorescence in cyclohexane, toluene, 1,4-dioxane, CHCl ₃ , and CH ₂ Cl ₂ (left) and in mixtures of cyclohexane and CH ₂ Cl ₂ (right)7
Computational Data7
Table S1. Energies of optimized geometries (PCM(cyclohexane)/B3LYP/6-31+G(d,p))
Fluorescence Lifetime Measurements
Figure S8. TCSPC measurements of new mixed-bridge macrocycles
Experimental
General methods
Synthesis of N-hexyl-4-bromo-5-iodophthalimide9
Synthesis of mixed bridged intermediates and macrocycles10
UV-vis and Fluorescence Spectroscopy16
Computational Chemistry
NMR Spectra17
Figure S9. ¹ H NMR spectrum (300 MHz, DMSO- d_6) of compound S317
Figure S10. ¹³ C NMR spectrum (125 MHz, DMSO- <i>d</i> ₆) of compound S3
Figure S11. ¹ H NMR spectrum (300 MHz, DMSO- <i>d</i> ₆) of compound S4
Figure S12. ¹³ C NMR spectrum (125 MHz, DMSO- <i>d</i> ₆) of compound S420

Figure S13. ¹ H NMR spectrum (300 MHz, DMSO- <i>d</i> ₆) of compound S5	
Figure S14. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound S6	
Figure S15. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound S6.	
Figure S16. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 1a.	
Figure S17. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 1a.	25
Figure S18. ¹ H NMR spectrum (300 MHz, CDCl ₃) of compound 2a.	
Figure S19. ¹³ C NMR spectrum (75 MHz, CDCl ₃) of compound 2a.	27
Figure S20. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 3a.	
Figure S21. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 3a.	
Figure S22. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound D(mP/Th)A	
Figure S23. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound D(mP/Th)A	
Figure S24. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound D(mP/Th)D	
Figure S25. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound D(mP/Th)D	
Figure S26. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 1b	
Figure S27. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 1b.	
Figure S28. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 2b	
Figure S29. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 2b.	
Figure S30. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 3b	
Figure S31. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 3b.	
Figure S32. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound H(mP/Th)H.	
Figure S33. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound H(mP/Th)H	41
Figure S34. ¹ H NMR spectrum (300 MHz, CDCl ₃) of compound 1c.	
Figure S35. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 1c.	
Figure S36. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 2c.	44
Figure S37. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 2c.	
Figure S38. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound 3c (small amount of grease impurity)	46
Figure S39. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound 3c (small amount of grease impurity)	47
Figure S40. ¹ H NMR spectrum (500 MHz, CDCl ₃) of compound A(mP/Th)A	
Figure S41. ¹³ C NMR spectrum (125 MHz, CDCl ₃) of compound A(mP/Th)A	
References	50

Supplemental Figures



Figure S1. UV–vis and fluorescence spectra of **H(mP/Th)H**, **D(mP/Th)D**, and **A(mP/Th)A** in cyclohexane (black) and CH₂Cl₂ (blue).



Figure S2. UV-vis and fluorescence spectra of D(mP/Th)A in in cyclohexane (black), toluene (blue), 1,4-dioxane (red), CHCl₃ (green) and CH₂Cl₂ (purple).



Figure S3. Optimized geometries and frontier molecular orbitals of A(mP/Th)A' and D(mP/Th)D'.



Figure S4. TD-DFT-calculated UV-vis transitions for **H(mP/Th)H'**, **D(mP/Th)D'**, **A(mP/Th)A'**, and **D(mP/Th)A'** at the TD/PCM(Cyclohexane)/CAM-B3LYP/6-311+G(2d,2p)//PCM/B3LYP/6-31+G(d,p) level. The solid lines are the simulated spectra based on the transitions with a 0.333 eV half-width at half-height. The dotted lines are the experimental spectra in cyclohexane (a.u.).



Figure S5. Lowest energy UV–vis transition (cyclohexane) vs PCM(cyclohexane)/CAM-B3LYP/6-311+G(2d,2p)//B3LYP/6-31+G(d) HOMO–LUMO gap for macrocycles H(mP/Th)H, D(mP/Th)D, and A(mP/Th)A.



Figure S6. Comparison of the UV-vis (left) and fluorescence (right) spectra of **D(mP/Th)A**, **D(Th)A**, and **D(Th)**₂**A**. The spectra of the latter two compounds were previously reported.¹

Lippert-Mataga Analysis

The fluorescence solvatochromism of D(mP/Th)A was analyzed using Weller's modification of the Lippert-Mataga equation:²

$$\overline{\nu}_f = -\frac{2\mu_e^2}{hca^3}\Delta f' + \overline{\nu}_0 \tag{1}$$

where \bar{v}_f is the fluorescence emission maximum, \bar{v}_0 is the emission maximum in vacuum, a^3 is the volume of the Onsager cavity (estimated from the total volume of a PM3-minimized model of the structure), and $\Delta f'$ is a solvent-dependent parameter calculated from its dielectric constant (ε) and refractive index (*n*):

$$\Delta f' = \frac{\varepsilon - 1}{2\varepsilon + 1} - \frac{n^2 - 1}{4n^2 + 2} \tag{2}$$

Thus, \bar{v}_f was plotted against $\Delta f'$ for both the five different solvents used (Figure 1) and for mixtures of

cyclohexane and CH_2Cl_2 , shown in Figure S7. The plot in structurally different solvents yields a reasonably good linear fit given that eq 1 is an approximation that neglects second-order effects and solvent-specific interactions.³



Figure S7. Lippert–Mataga plots of **D(mP/Th)A** fluorescence in cyclohexane, toluene, 1,4-dioxane, CHCl₃, and CH₂Cl₂ (left) and in mixtures of cyclohexane and CH₂Cl₂ (right).

Computational Data

Please note that Cartesian coordinates of optimized geometries are included in a separate, plain text SI file.

Compound	Imag. Freq.	Energy (<i>E</i> _h)	ZPC $(E_h)^a$	Total (E_h)
H(mP/Th)H'	0	-1549.665503	0.328147	-1549.337355
D(mP/Th)D'	0	-2007.776843	0.458046	-2007.318797
A(mP/Th)A'	0	-2111.381468	0.357865	-2111.023603
D(mP/Th)A'	0	-2059.579944	0.407916	-2059.172028

Table S1. Energies of optimized geometries (PCM(cyclohexane)/B3LYP/6-31+G(d,p))

^{*a*} Unscaled.

Fluorescence Lifetime Measurements



Figure S8. TCSPC measurements of new mixed-bridge macrocycles.

Experimental

General methods

Unless otherwise noted, all reagents and solvents were purchased from commercial sources and used without further purification. Anhydrous THF was obtained by distillation from sodium/benzophenone. Flash column chromatography was performed using Silicycle SiliaFlash P60 (40-63 µm, 230-400 mesh). Gel permeation chromatography was performed using a Waters Breeze 2 HPLC equipped with a 19×300 mm Ultrastyragel 500 Å GPC column with THF as the eluent. Melting points were determined using a Thermal Analysis Q20 differential scanning calorimeter at a heating rate of 10 °C/min or by a polarized optical microscope with a Linkam LTS 350 variable temperature stage. NMR spectra were measured in

deuterated solvents (CDCl₃ or DMSO- d_6) using Bruker Avance 300 or 500 MHz spectrometers. Chemical shifts are reported in δ (ppm) relative to TMS, with the residual solvent protons used as internal standards (CDCl₃: 7.26 for ¹H, 77.16 for ¹³C; DMSO- d_6 : 2.50 for ¹H, 39.52 for ¹³C). Low resolution mass spectra were performed using a Shimadzu LC-MS in ESI or APCI modes and MALDI-MS samples were recorded using a Bruker Ultraflex MALDI spectrometer in reflectron mode with dithranol as the matrix. In many cases, the MALDI samples were doped with CuI to promote formation of Cu⁺ adducts. High resolution mass spectra were obtained from Ohio State University microanalyses group and University of Cincinnati mass spectrometry facility.

Synthesis of N-hexyl-4-bromo-5-iodophthalimide



4-Bromo-5-iodophthalimide (S3). 4-Bromophthalimide **S2**⁴ (10.75 g, 0.047 mol) in 20% oleum (28.6 mL, 54.9 g, 0.308 mol) and I₂ (12.05 g, 0.047 mmol) was vigorously stirred at 80–85 °C for 40 h. The dark viscous solution was poured into ice (100 g) and the white precipitate was collected by vacuum filtration. The precipitate was washed in the following order: 2% (w/v) K₂CO₃(aq), satd Na₂S₂O₃(aq), and water to give a yellow precipitate. The crude solid was dried under high vacuum for 18 h to give a pale yellow solid in quantitative yield. The solid **S3** was used in the next step without further purification: mp 200 °C dec; ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.08 (s, 1H), 8.28 (s, 1H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 110.3, 126.9, 132.8, 134.2, 134.4, 135.8, 167.8, 168.1; MS (ESI, negative ion mode) calcd for C₈H₂BrINO₂ ([M–H]⁻) 349.8, found 349.8; HRMS (ESI) calcd for C₈H₃BrINO₂Na ([M+Na]⁺) 373.8290, found 373.8253.

4-Bromo-5-iodobenzoic acid (S4). A suspension of **S3** (16.70 g, 0.047 mol) in 10% (w/v) KOH(aq) (50 mL) was heated under reflux for 18 h. The clear dark solution was acidified with aqueous 6 M HCl solution to pH 2 and the resulting precipitate was collected by vacuum filtration. The precipitate was

washed with several volumes of water and the solid was dried under high vacuum to give a **S4** as a yellow solid (7.74 g, 44% over 2 steps): mp >300 °C dec; ¹H NMR (300 MHz, DMSO- d_6) δ 8.12 (s, 1H), 8.37 (s, 1H); ¹³C NMR (125 MHz, DMSO- d_6) δ 105.8, 132.2, 133.9, 134.2, 135.3, 135.3, 166.6, 166.9; MS (ESI, negative ion mode) calcd for C₈H₃BrIO₄ (M⁻) 368.8, found 368.7.

N-Hexyl-4-bromo-5-iodophthalimide (S6). To a round bottom flask containing S4 (7.74 g, 0.0208 mol) was added SOCl₂ (13 mL, 21.3 g, 0.179 mol) at 60 °C and the yellow suspension was heated to 90 °C for 16 h. The excess SOCl₂ was removed under reduced pressure and the crude yellow solid was dried under high vacuum to give 4-bromo-5-iodophthalic anhydride S5 which was used in the next step without further purification: ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.94 (s, 1H), 8.16 (s, 1H). A suspension of S5 (7.34 g, 0.0208 mol) and hexylamine (2.75 mL, 2.10 g, 0.0208 mol) in toluene (40 mL) was heated under reflux for 18 h. The reaction mixture was concentrated under reduced pressure. Purification by flash chromatography (19:1 hexanes/Et₂O then Et₂O) followed by trituration (Et₂O) gave S6 as a beige solid (4.83 g, 53% over 2 steps): mp 102–103 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.85 (t, *J* = 6.8 Hz, 3H), 1.28 (br s, 6H), 1.63 (m, 2H), 3.63 (t, *J* = 7.3 Hz, 2H), 8.02 (s, 1H), 8.28 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.0, 22.5, 26.5, 28.4, 31.3, 38.5, 108.1, 126.9, 131.3, 132.9, 134.8, 136.1, 166.3, 166.6.

Synthesis of mixed bridged intermediates and macrocycles



Compound 1a. A Schlenk tube containing $Pd(OAc)_2$ (26 mg, 0.116 mmol), CuI (19 mg, 0.099 mmol), PPh₃ (169 mg, 0.64 mmol) and 1-bromo-2-iodoveratrole⁵ (1.00 g, 2.91 mmol) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of 2-ethynyl-5-(triisopropylsilylethynyl)thiophene (1.00 g, 3.5 mmol) in HN^iPr_2 (25 mL). The suspension was degassed by three freeze-pump-thaw cycles and heated with stirring at 75 °C for 18 h. The resulting suspension was diluted with CH_2Cl_2 (30 mL), washed with water (2 × 15 mL), dried (MgSO₄), filtered, and

concentrated. Purification by flash chromatography (9:1 hexanes/CH₂Cl₂ then CH₂Cl₂) gave **1a** as a brown oil (1.30 g, 89 %, contains ~15% 1-bromo-2-iodoveratrole): ¹H NMR (500 MHz, CDCl₃) δ 1.12 (s, 21H), 3.88 (s, 3H), 3.89 (s, 3H), 6.99 (s, 1H), 7.04 (s, 1H), 7.10 (d, *J* = 3.8 Hz, 1H), 7.12 (d, *J* = 3.8 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 11.3, 18.6, 56.1, 56.2, 85.1, 92.5, 97.1, 98.8, 114.9, 115.2, 116.8, 124.1, 125.2, 131.6, 132.3, 148.2, 150.1; MS (APCI) calcd for C₂₅H₃₁BrO₂SSi (M⁺) 502.09, found 502.2; HRMS (ESI) calcd for C₂₅H₃₁BrNaO₂SSi ([M+Na]⁺) 525.0895, found 525.0915.

Compound 2a. A Schlenk tube containing Pd(P^{*i*}Bu₃)₂ (44 mg, 0.086 mmol), CuI (16 mg, 0.084 mmol), and DABCO (2.2 g) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of **1a** (1.00 g, 2.0 mmol) and 1-*tert*-butyl-3-ethynyl-5-(triisopropylsilylethynyl)benzene (1.80 g, 5.3 mmol) in toluene (45 mL). The suspension was degassed by three freeze-pump-thaw cycles and stirred at room temperature for 18 h. The resulting suspension was concentrated and diluted with CH₂Cl₂ (30 mL), washed with water (2 × 15 mL), dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (hexanes then 2:8 hexanes/toluene) gave **2a** as a brown gummy solid (1.13 g, 74%): mp 64–65 °C dec; ¹H NMR (300 MHz, CDCl₃) δ 1.13 (s, 21H), 1.15 (s, 21H), 1.32 (s, 9H), 3.93 (s, 3H), 3.93 (s, 3H), 7.00 (s, 1H), 7.03 (s, 1H), 7.08 (d, *J* = 3.8 Hz, 1H), 7.12 (d, *J* = 3.8 Hz, 1H), 7.44 (t, *J* = 1.7 Hz, 1H), 7.51 (t, *J* = 1.3 Hz, 1H), 7.56 (t, *J* = 1.5 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 11.3, 11.4, 18.6, 18.7, 31.2, 34.7, 56.1, 85.1, 87.9, 90.5, 92.4, 92.8, 96.9, 98.8, 106.8, 113.6, 114.0, 118.3, 118.9, 123.1, 123.5, 124.5, 124.9, 128.8, 128.9, 131.3, 132.2, 132.5, 149.2, 149.4, 151.5; MALDI-TOF-MS (dithranol) calcd for C₄₈H₆₅O₂SSi₂ ([M+H]⁺) 761.4, found 761.2; HRMS (ESI) calcd for C₄₈H₆₄NaO₂SSi₂ ([M+Na]⁺) 783.4063, found 783.4079.

Compound 3a. To solution of **2a** (1.75 g, 2.3 mmol) in THF (15 mL) was added dropwise a 1.0 M solution of TBAF in THF (5.0 mL, 5.0 mmol). The mixture was stirred at room temperature for 2 h under an argon atmosphere. The resulting solution was diluted with CH_2Cl_2 (20 mL), washed with brine, water, dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (9:1 hexanes/EtOAc) gave **3a** as a brown oil (0.65 g, 63%): ¹H NMR (500 MHz, CDCl₃) δ 1.31 (s, 9H), 3.07 (s, 1H), 3.37 (s, 1H), 3.92 (s, 3H), 3.93 (s, 3H), 6.99 (s, 1H), 7.02 (s, 1H), 7.13 (d, *J* = 3.9 Hz, 1H), 7.15 (d, *J* = 3.8 Hz, 1H), 7.48 (t, *J* = 1.4 Hz, 1H), 7.54 (t, *J* = 1.4 Hz, 1H), 7.57 (t, *J* = 1.8 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 31.1, 34.7, 56.1, 76.5, 77.2, 82.2, 83.3, 84.8, 88.2, 92.3, 93.1, 113.6, 113.9, 118.2, 118.9, 122.1, 123.2, 125.2, 129.1, 131.2, 132.3, 133.0, 149.2, 149.5, 151.7; MALDI-TOF-MS (dithranol) calcd for $C_{30}H_{24}O_2S$ (M⁺) 448.1, found 448.0; HRMS (ESI) calcd for $C_{30}H_{24}NaO_2S$ ([M+Na]⁺) 471.1395, found 471.1411.

Macrocycle D(Th/mP)A. A Schlenk tube containing Pd(P'Bu₃)₂ (2.5 mg, 5 µmol) and *N*-hexyl-4,5diiodophthalimide¹ (58 mg, 0.12 mmol) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of **3a** (44 mg, 0.098 mmol) in Et₃N/toluene (3:7, 50 mL). The suspension was degassed by three freeze-pump-thaw cycles and stirred at room temperature for 18 h. The resulting suspension was concentrated and diluted with CH₂Cl₂ (30 mL), washed with water (3 × 20 mL), dried (MgSO₄), filtered, and concentrated. Purification by gel permeation chromatography gave **D(Th/mP)A** as a light orange solid (16.5 mg, 25 %): mp >300 °C dec; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J* = 6.4 Hz, 3H), 1.31 (br s, 6H), 1.36 (s, 9H), 1.63 (m, 2H), 3.60 (t, *J* = 7.8 Hz, 2H), 3.88 (s, 3H), 3.93 (s, 3H), 6.77 (s, 1H), 6.94-6.95 (m, 3H), 7.43 (t, 1H), 7.54 (t, 1H), 7.70 (s, 1H), 7.89 (s, 1H), 8.50 (t, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.1, 22.5, 26.5, 28.5, 31.2, 31.3, 34.8, 38.2, 55.9, 56.0, 85.3, 87.8, 88.6, 90.5, 92.1, 95.7, 97.6, 112.3, 114.6, 117.7, 119.9, 122.3, 123.5, 123.8, 124.5, 126.9, 127.2, 128.3, 129.0, 129.4, 130.1, 130.3, 131.8, 134.1, 148.9, 149.3, 151.5, 167.1, 167.2; MALDI-TOF-MS (dithranol) calcd for C₄₄H₃₇NO₄S (M⁺) 675.2, found 675.0; HRMS (ESI) calcd for C₄₄H₃₇NNaO₄S ([M+Na]⁺) 698.2341, found 698.2333. Prior to UV–vis and fluorescence spectroscopy, the compound was recrystallized from hexanes/CH₂Cl₂.

Macrocycle D(Th/mP)D. A Schlenk tube containing $Pd(P'Bu_3)_2$ (2.7 mg, 5.3 µmol), 1,2diiodoveratrole^{6,7} (43 mg, 0.11 mmol) and DABCO (2.2 g) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of **3a** (41 mg, 0.091 mmol) in toluene (45 mL). The suspension was degassed by three freeze-pump-thaw cycles and stirred at room temperature for 18 h. The resulting suspension was concentrated and diluted with CH₂Cl₂ (30 mL), washed with water (3 × 20 mL), dried (MgSO₄), filtered, and concentrated. Purification by gel permeation chromatography followed by flash chromatography (2:8 hexanes/CH₂Cl₂) gave **D(Th/mP)D** as a yellow solid (11.3 mg, 21%): mp >300 °C dec; ¹H NMR (500 MHz, CDCl₃) δ 1.36 (s, 9H), 3.91 (s, 6H), 3.95 (s, 6H), 6.91 (s, 2H), 7.01 (s, 2H), 7.08 (s, 2H), 7.52 (t, *J* = 1.4 Hz, 2H), 8.52 (t, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 31.2, 34.8, 56.0, 56.1, 85.4, 88.4, 92.2, 96.7, 112.4, 114.8, 118.0, 120.0, 123.3, 125.4, 128.5, 128.6, 133.7, 149.1, 149.4, 151.4; MALDI-TOF-MS (dithranol) calcd for C₃₈H₃₀O₄S (M⁺) 582.2, found 581.9; HRMS (ESI) calcd for C₃₈H₃₀NaO₄S ([M+Na]⁺) 605.1763, found 605.1750.

Compound 1b. A Schlenk tube containing $Pd(OAc)_2$ (35 mg, 0.16 mmol), CuI (20 mg, 0.10 mmol) and PPh₃ (203 mg, 0.77 mmol) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of 1-bromo-2-iodobenzene (0.454 mL, 1.00 g, 3.53 mmol) and 2-ethynyl-5-(triisopropylsilylethynyl)thiophene⁸ (1.22 g, 4.23 mmol) in $HN'Pr_2$ (25 mL). The suspension was degassed by three freeze-pump-thaw cycles and heated with stirring at 75 °C for 18 h. The resulting

suspension was diluted with CH₂Cl₂ (30 mL), washed with water (2 × 15 mL), dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (hexanes, then 19:1 hexanes/Et₂O, then 1:1 hexanes/Et₂O) gave **1b** as a clear yellow oil (0.99 g, 65%): ¹H NMR (500 MHz, CDCl₃) δ 1.13 (s, 21H), 7.11 (d, *J* = 3.9 Hz, 1H), 7.16 (d, *J* = 3.9 Hz, 1H), 7.19 (td, *J* = 7.8, 1.6 Hz, 1H), 7.29 (td, *J* = 7.6, 1.2 Hz, 1H), 7.52 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.61 (dd, *J* = 8.0, 1.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 11.3, 18.6, 86.7, 92.2, 97.3, 98.7, 107.6, 108.6, 111.4, 113.3, 124.9, 125.4, 125.6, 127.1, 129.7, 131.9, 132.3, 132.5, 133.1; MS (APCI) calcd for C₂₃H₂₇BrSSi (M⁺) 442.1, found 442.2; HRMS (ESI) calcd for C₂₃H₂₇BrNaSSi ([M+Na]⁺) 465.0684, found 465.0664.

Compound 2b. A Schlenk tube containing Pd(P'Bu₃)₂ (48 mg, 0.094 mmol), CuI (18 mg, 0.095 mmol) and DABCO (2 g) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of **1b** (1.00 g, 2.3 mmol) and 1-*tert*-butyl-3-ethynyl-5-(triisopropylsilylethynyl)benzene^{9,10} (0.920 g, 2.7 mmol) in toluene (50 mL). The suspension was degassed by three freeze-pump-thaw cycles and stirred at room temperature for 18 h. The resulting suspension was concentrated and diluted with CH₂Cl₂ (30 mL), washed with water (2 × 15 mL), dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (hexanes then Et₂O) gave **2b** as a brown gummy solid (1.44 g, 89%): mp 43–44 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.13 (s, 21H), 1.15 (s, 21H), 1.32 (s, 9H), 7.09 (d, *J* = 3.9 Hz, 1H), 7.14 (d, *J* = 3.8 Hz, 1H), 7.32 (m, 2H), 7.45 (t, *J* = 1.4, 1H), 7.52–7.57 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 11.3, 18.6, 18.7, 31.1, 34.7, 86.4, 87.8, 90.6, 92.6, 93.7, 112.4, 113.3, 122.9, 123.5, 124.1, 125.3, 125.7, 128.1, 128.3, 129.0, 129.1, 131.5, 131.7, 131.8, 132.4, 132.5, 151.6; MS (APCI) calcd for C₄₆H₆₀SSi₂ (M⁺) 700.4, found 700.5; HRMS (ESI) calcd for C₄₆H₆₀NaSSi₂ ([M+Na]⁺) 723.3852, found 723.3862.

Compound 3b. To solution of **2b** (1.47 g, 2.1 mmol) in THF (10 mL) was added dropwise a 1.0 M solution of TBAF in THF (4.6 mL, 4.6 mmol). The mixture was stirred at room temperature for 2 h under an argon atmosphere. The resulting solution was diluted with CH_2Cl_2 (20 mL), washed with brine and water, then dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (9:1 hexanes/EtOAc) gave **3b** as a clear pale brown oil (0.23 g, 26%): ¹H NMR (500 MHz, CDCl₃) δ 1.31 (s, 9H), 3.08 (s, 1H), 3.38 (s, 1H), 7.16 (s, 2H), 7.30–7.35 (m, 2H), 7.50–7.58 (m, 5H); ¹³C NMR (125 MHz, CDCl₃) δ 31.1, 34.7, 76.5, 77.3, 82.3, 83.3, 86.1, 88.1, 92.9, 93.6, 122.2, 123.1, 123.6, 124.9, 125.2, 125.7, 128.2, 128.5, 129.3, 129.5, 131.5, 131.6, 131.8, 132.5, 133.0, 151.7; MALDI-TOF-MS (dithranol) calcd for C₅₆H₄₀S₂ (2M⁺) 776.25, found 776.1; HRMS (ESI) calcd for C₂₈H₂₀NaS ([M+Na]⁺) 411.1183, found 411.1184.

Macrocycle H(mP/Th)H. A Schlenk tube containing Pd(P^tBu₃)₂ (3.6 mg, 7.0 µmol) and DABCO

(0.8 g) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of **3b** (42 mg, 0.108 mmol) and 1,2-diiodobenzene (17 µL, 43 mg, 0.130 mmol) in toluene (55 mL). The suspension was degassed by three freeze-pump-thaw cycles and stirred at room temperature for 18 h. The resulting suspension was concentrated and diluted with CH_2Cl_2 (30 mL), washed with water (3 × 20 mL), dried (MgSO₄), filtered, and concentrated. Purification by gel permeation chromatography gave **H(mP/Th)H** as a yellow solid (15.0 mg, 30%): mp >300 °C dec; ¹H NMR (500 MHz, CDCl₃) δ 1.37 (s, 9H), 7.06 (s, 2H), 7.29–7.34 (m, 4H), 7.44–7.46 (m, 2H), 7.55 (d, *J* = 1.5 Hz, 2H), 7.60–7.62 (m, 2H), 8.54 (t, *J* = 1.4 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 31.2, 34.8, 86.5, 88.4, 93.4, 96.6, 123.1, 124.9, 125.5, 126.8, 128.1, 128.4, 129.08, 129.1, 130.3, 132.6, 133.9, 151.5; MALDI-TOF-MS (dithranol) calcd for C₃₄H₂₂S (M⁺) 462.14, found 461.84; HRMS (ESI) calcd for C₃₄H₂₂NaS ([M+Na]⁺) 485.1340, found 485.1357.

Compound 1c. A Schlenk tube containing Pd(OAc)₂ (23 mg, 0.102 mmol), CuI (13 mg, 0.068 mmol), PPh₃ (129 mg, 0.49 mmol) and *N*-hexyl-4-bromo-5-iodophthalimide (1.00 g, 2.3 mmol) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of 2-ethynyl-5-(triisopropylsilylethynyl)thiophene (0.790 g, 2.7 mmol) in HN⁴Pr₂ (25 mL). The suspension was degassed by three freeze-pump-thaw cycles and heated with stirring at 75 °C for 18 h. The resulting suspension was diluted with CH₂Cl₂ (30 mL), washed with water (2 × 15 mL), dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (1:1 hexanes/CH₂Cl₂) gave **1c** as a light brown solid (1.15 g, 84%): mp 96–97 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.87 (t, *J* = 6.6 Hz, 3H), 1.21 (s, 21H), 1.31 (br s, 6H), 1.63 (m, 2H), 3.66 (t, *J* = 7.4 Hz, 2H), 7.14 (d, *J* = 3.8 Hz, 1H), 7.23 (d, *J* = 3.8 Hz, 1H), 7.91 (s, 1H), 8.05 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 11.3, 14.0, 18.6, 22.5, 26.5, 28.4, 31.3, 38.5, 91.4, 91.5, 98.4, 98.5, 122.4, 126.9, 127.1, 127.4, 130.5, 130.8, 131.2, 131.8, 132.4, 133.3, 166.6, 167.0; MS (APCI) calcd for C₃₁H₃₈BrNO₂SSi (M⁺) 595.15, found 595.3; HRMS (ESI) calcd for C₃₁H₃₈BrNNaO₂SSi ([M+Na]⁺) 618.1474, found 618.1481.

Compound 2c. A Schlenk tube containing $Pd(P^tBu_3)_2$ (39 mg, 0.076 mmol), CuI (14 mg, 0.074 mmol), and DABCO (2.1 g) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of **1c** (1.15 g, 1.9 mmol) and 1-*tert*-butyl-3-ethynyl-5-(triisopropylsilylethynyl)benzene (0.78 g, 2.3 mmol) in toluene (50 mL). The suspension was degassed by three freeze-pump-thaw cycles and stirred at room temperature for 18 h. The resulting suspension was concentrated and diluted with CH₂Cl₂ (30 mL), washed with water (2 × 15 mL), dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (8:2 hexanes/CH₂Cl₂ then 1:1 hexanes/CH₂Cl₂) gave **2c** as a light brown solid

(1.40 g, 85%): mp 54–55 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J* = 6.8 Hz, 3H), 1.13 (s, 21H), 1.15 (s, 21H), 1.33 (s, 15H), 1.68 (m, 2H), 3.68 (t, *J* = 7.6 Hz, 2H), 7.11 (d, *J* = 3.8 Hz, 1H), 7.21 (d, *J* = 3.8 Hz, 1H), 7.50 (t, *J* = 1.7 Hz, 1H), 7.54 (t, *J* = 1.4 Hz, 1H), 7.58 (t, *J* = 1.6 Hz, 1H), 7.95 (d, *J* = 0.6 Hz, 1H), 7.98 (d, *J* = 0.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 11.3, 14.0, 18.7, 22.5, 26.5, 28.5, 31.1, 31.3, 34.7, 38.4, 86.9, 90.7, 91.1, 91.7, 98.0, 98.4, 106.4, 122.0, 122.9, 123.8, 125.8, 126.2, 126.7, 129.1, 129.9, 130.6, 130.8, 130.9, 130.9, 132.6, 132.7, 132.9, 151.8, 167.1; MALDI-TOF-MS (dithranol) calcd for C₅₄H₇₂NO₂SSi₂ (M+H⁺) 854.5, found 854.3; HRMS (ESI) calcd for C₅₄H₇₁NNaO₂SSi₂ ([M+Na]⁺) 876.4642, found 876.4639.

Compound 3c. To solution of **2c** (0.250 g, 0.29 mmol) in THF (15 mL) was added glacial AcOH (36.5 μ L, 0.64 mmol) followed by a 1.0 M solution of TBAF in THF (0.64 mL, 0.64 mmol). The mixture was stirred at room temperature for 2 h under an argon atmosphere. The resulting solution was diluted with CH₂Cl₂ (10 mL), washed with brine and water, then dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (19:1 hexanes/EtOAc) gave **3c** as a brown solid (52 mg, 33%): mp 150–151 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J* = 6.8 Hz, 3H), 1.33 (s, 15H), 1.68 (m, 2H), 3.11 (s, 1H), 3.42 (s, 1H), 3.67 (t, *J* = 7.6 Hz, 2H), 7.17 (d, *J* = 3.8 Hz, 1H), 7.22 (d, *J* = 3.8 Hz, 1H), 7.54 (t, *J* = 1.7 Hz, 1H), 7.57 (t, *J* = 1.4 Hz, 1H), 7.59 (t, *J* = 1.6 Hz, 1H), 7.93 (d, *J* = 0.6 Hz, 1H), 7.95 (d, *J* = 0.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.0, 22.5, 26.5, 28.5, 31.0, 31.2, 34.8, 38.4, 76.1, 77.6, 82.9, 83.0, 87.1, 90.3, 91.9, 97.8, 122.1, 122.4, 123.6, 125.0, 125.8, 126.2, 129.4, 130.3, 130.5, 130.8, 131.0, 132.8, 133.2, 151.9, 167.1, 167.2; MALDI-TOF-MS (dithranol) calcd for C₃₆H₃₁NO₂S (M⁺) 541.20, found 541.91; HRMS (ESI) calcd for C₃₆H₃₁NNaO₂S ([M+Na]⁺) 564.1973, found 564.1965.

Macrocycle A(mP/Th)A. A Schlenk tube containing Pd(P'Bu₃)₂ (5.0 mg, 9.8 µmol), *N*-hexyl-4,5diiodophthalimide¹ (47 mg, 0.097 mmol) and DABCO (1.00 g) was evacuated and backfilled with argon (3×). To this solid mixture was added a solution of **3c** (44 mg, 0.081 mmol) in toluene (40 mL). The suspension was degassed by three freeze-pump-thaw cycles and stirred at room temperature for 18 h. The resulting suspension was concentrated and diluted with CH_2Cl_2 (30 mL), washed with water (3 × 20 mL), dried (MgSO₄), filtered, and concentrated. Purification by gel permeation chromatography gave **A(mP/Th)A** as a light orange solid (18.7 mg, 30%); mp >300 °C dec; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J* = 6.3 Hz, 6H), 1.32 (br s, 12H), 1.39 (s, 9H), 1.67 (m, 4H), 3.65 (t, *J* = 7.5 Hz, 4H), 7.12 (s, 2H), 7.59 (s, 2H), 7.77 (s, 2H), 7.95 (s, 2H), 8.54 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.0, 22.5, 26.5, 28.5, 31.2, 31.4, 34.9, 38.4, 87.8, 90.1, 96.1, 97.4, 122.4, 124.7, 125.6, 127.0, 129.9, 130.2, 130.5, 130.8, 130.9, 131.9, 134.3, 152.1, 167.0; MALDI-TOF-MS (dithranol) calcd for C₅₀H₄₄CuN₂O₄S ([M+Cu]⁺) 831.2, found 831.0; HRMS (ESI) calcd for $C_{100}H_{88}N_4NaO_8S_2$ ([2M+Na]⁺) 1559.5941, found 1559.5936. Prior to UV–vis and fluorescence spectroscopy, the compound was recrystallized from hexanes/CH₂Cl₂.

UV-vis and Fluorescence Spectroscopy

UV–vis and fluorescence spectroscopy were obtained for solutions in commercial spectrophotometricgrade solvents. Spectra were obtained in 10 mm quartz cuvettes. Emission spectra are corrected.¹¹ Quantum yields were determined using standard methods for nitrogen-sparged solutions relative to quinine bisulfate in 0.5 M H₂SO₄ ($\Phi_f = 0.54$) (emission between 350 and 600 nm) or rhodamine 101 in EtOH ($\Phi_f = 0.91$) (emission above 550 nm). The absorbance of the solutions was kept below 0.10 to avoid the inner filter effect. The quinine bisulfate was cross-checked against 9,10-diphenylanthracene in cyclohexane ($\Phi_f = 0.91$) and the rhodamine 101 with cresyl violet in MeOH ($\Phi_f = 0.54$); in both cases the measured quantum yields agreed with literature values to within 10%. Fluorescence lifetimes were determined for nitrogen-sparged solutions.

Computational Chemistry

All calculations were performed using Gaussian 09, rev. B.01.¹² Geometries were visualized using VMD 1.9.1.¹³

NMR Spectra



Figure S9. ¹H NMR spectrum (300 MHz, DMSO-*d*₆) of compound **S3**.



Figure S10. ¹³C NMR spectrum (125 MHz, DMSO-*d*₆) of compound S3.



Figure S11. ¹H NMR spectrum (300 MHz, DMSO-*d*₆) of compound **S4**.



Figure S12. ¹³C NMR spectrum (125 MHz, DMSO-*d*₆) of compound S4.



Figure S13. ¹H NMR spectrum (300 MHz, DMSO-*d*₆) of compound **S5**.



Figure S14. ¹H NMR spectrum (500 MHz, CDCl₃) of compound S6.



Figure S15. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound S6.





Figure S16. ¹H NMR spectrum (500 MHz, $CDCl_3$) of compound 1a.



Figure S17. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 1a.



Figure S18. ¹H NMR spectrum (300 MHz, CDCl₃) of compound 2a.



Figure S19. ¹³C NMR spectrum (75 MHz, CDCl₃) of compound 2a.

4/26/2012 1:44:53 PM



Figure S20. ¹H NMR spectrum (500 MHz, CDCl₃) of compound 3a.



Figure S21. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3a.



Figure S22. ¹H NMR spectrum (500 MHz, CDCl₃) of compound D(mP/Th)A.



Figure S23. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound D(mP/Th)A.





Figure S24. ¹H NMR spectrum (500 MHz, CDCl₃) of compound D(mP/Th)D.



Figure S25. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound D(mP/Th)D.





Figure S26. ¹H NMR spectrum (500 MHz, CDCl₃) of compound 1b.



Figure S27. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 1b.



Figure S28. ¹H NMR spectrum (500 MHz, CDCl₃) of compound 2b.



Figure S29. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 2b.



Figure S30. ¹H NMR spectrum (500 MHz, CDCl₃) of compound 3b.



Figure S31. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3b.



Figure S32. ¹H NMR spectrum (500 MHz, CDCl₃) of compound H(mP/Th)H.



Figure S33. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound H(mP/Th)H.

```
8/7/2012 7:24:35 AM
```



Figure S34. ¹H NMR spectrum (300 MHz, CDCl₃) of compound 1c.



Figure S35. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 1c.





Figure S36. ¹H NMR spectrum (500 MHz, CDCl₃) of compound 2c.





Figure S37. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 2c.



Figure S38. ¹H NMR spectrum (500 MHz, CDCl₃) of compound 3c (small amount of grease impurity).



Figure S39. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound 3c (small amount of grease impurity).



Figure S40. ¹H NMR spectrum (500 MHz, CDCl₃) of compound A(mP/Th)A.



Figure S41. ¹³C NMR spectrum (125 MHz, CDCl₃) of compound A(mP/Th)A.

References

- (1) Leu, W. C. W.; Fritz, A. E.; Digianantonio, K. M.; Hartley, C. S. J. Org. Chem. 2012, 77, 2285–2298.
- (2) Beens, H.; Knibbe, H.; Weller, A. J. Chem. Phys. **1967**, 47, 1183–1184.
- (3) Lakowicz, J. R. *Principles of fluorescence spectroscopy*; 3rd ed. Springer: New York, 2006.
- (4) Wolk, J. L.; Frimer, A. A. *Molecules* **2010**, *15*, 5561–5580.
- (5) Orito, K.; Hatakeyama, T.; Takeo, M.; Suginome, H. Synthesis 1995, 1273–1277.
- (6) Kovalenko, S. V.; Peabody, S.; Manoharan, M.; Clark, R. J.; Alabugin, I. V. *Org. Lett.* **2004**, *6*, 2457–2460.
- (7) Lacour, J.; Monchaud, D.; Bernardinelli, G.; Favarger, F. Org. Lett. 2001, 3, 1407–1410.
- (8) Roue, S.; Lapinte, C. J. Organomet. Chem. 2005, 690, 594–604.
- (9) Hoger, S.; Meckenstock, A.; Pellen, H. J. Org. Chem. 1997, 62, 4556–4557.
- (10) Tobe, Y.; Utsumi, N.; Nagano, A.; Sonoda, M.; Naemura, K. *Tetrahedron* **2001**, *57*, 8075–8083.
- (11) Pfeifer, D.; Hoffmann, K.; Hoffmann, A.; Monte, C.; Resch-Genger, U. J. Fluoresc. 2006, 16, 581–587.
- (12) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; J A Montgomery, J.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. *Gaussian 09*, Rev. B.0.1; Gaussian, Inc.: Wallingford, CT, **2010**.
- (13) Humphrey, W.; Dalke, A.; Schulten, K. J. Molec. Graphics 1996, 14, 33–38.